Search

Your search keyword '"Communicable diseases -- Drug therapy"' showing total 1,142 results
Start Over Descriptor "Communicable diseases -- Drug therapy"
Sorry, I don't understand your search. ×
1,142 results on '"Communicable diseases -- Drug therapy"'

151. Global Avian Influenza (Infectious Disease) Drugs Development Market Report 2021: Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type

Subjects
Avian influenza -- Drug therapy, Communicable diseases -- Drug therapy, Industrial research, Research and development, Banking, finance and accounting industries, Business
Abstract

Dublin, April 30, Apr 30, 2021 (GLOBE NEWSWIRE via COMTEX) -- The 'Avian Influenza (Infectious Disease) - Drugs in Development, 2021' report has been added to ResearchAndMarkets.com's offering. The report [...]

Published
2021

152. Global Therapeutic Landscape of Avian Influenza Drugs in Development 2021

Subjects
Avian influenza -- Drug therapy, Communicable diseases -- Drug therapy, Drugs, Industrial research, Research and development, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following press release: The 'Avian Influenza (Infectious Disease) - Drugs in Development, 2021' report has been added to ResearchAndMarkets.com's offering. Avian Influenza (Infectious [...]

Published
2021

153. Global Therapeutic Landscape of Avian Influenza Drugs in Development 2021

Subjects
Avian influenza -- Drug therapy, Communicable diseases -- Drug therapy, Drugs -- Reports, Industrial research -- Ireland -- United Kingdom, Research and development, Business, News, opinion and commentary
Abstract

DUBLIN, April 29, 2021 /PRNewswire/ -- The 'Avian Influenza (Infectious Disease) - Drugs in Development, 2021' report has been added toResearchAndMarkets.com's offering. Avian Influenza (Infectious Disease) - Drugs in Development, [...]

Published
2021

154. Avian Influenza (Infectious Disease) Drugs in Development, 2021 Report

Subjects
Avian influenza -- Drug therapy, Communicable diseases -- Drug therapy, Industrial research -- Reports, Research and development, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Avian Influenza (Infectious Disease) - Drugs in Development, 2021' report has been added to ResearchAndMarkets.com's offering. The report provides [...]

Published
2021

155. Avian Influenza (Infectious Disease) Drugs in Development, 2021 Report - ResearchAndMarkets.com

Subjects
Avian influenza -- Drug therapy, Communicable diseases -- Drug therapy, Industrial research -- Reports, Research and development, Business, Business, international
Abstract

DUBLIN -- The 'Avian Influenza (Infectious Disease) - Drugs in Development, 2021' report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive information on the therapeutics under development for [...]

Published
2021

156. Avian Influenza (Infectious Disease) Drugs in Development, 2021 Report

Subjects
Avian influenza -- Drug therapy, Communicable diseases -- Drug therapy, Drugs -- Reports, Industrial research -- Reports, Research and development, Business, Business, international
Abstract

M2 PRESSWIRE-April 28, 2021-: Avian Influenza (Infectious Disease) Drugs in Development, 2021 Report (C)1994-2021 M2 COMMUNICATIONS RDATE:28042021 The 'Avian Influenza (Infectious Disease) - Drugs in Development, 2021' report has been [...]

Published
2021

157. Roche to Use Oncimmune Infectious Disease Panel in COVID-19 Drug Trial

Subjects
Communicable diseases -- Drug therapy, Business, international, Law
Abstract

Oncimmune Holdings on Tuesday announced a contract with Roche Pharmaceuticals to utilize its infectious disease panel in a COVID-19 pneumonia drug trial. The trial, called COVACTA, will evaluate the drug [...]

Published
2021

158. Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse(TM) Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

Subjects
Communicable diseases -- Drug therapy, Diseases -- Relapse, Gene therapy, Immunotherapy, Papillomavirus infections -- Drug therapy, Business, News, opinion and commentary
Abstract

- Milestone represents the first patient dosed with an OTS AdenoVerse immunotherapy targeting infectious disease - - RRP is a rare, difficult-to-treat neoplastic disease caused by HPV 6 or HPV [...]

Published
2021

159. INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18

Subjects
Inovio Pharmaceuticals Inc. -- Company sales and earnings -- Product development, Communicable diseases -- Drug therapy, DNA, Dysplasia -- Drug therapy, Biotechnology industry -- Product development -- Company sales and earnings, Immunotherapy, Papillomavirus infections -- Drug therapy, Company earnings/profit, Business, News, opinion and commentary
Abstract

Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind, placebo-controlled trial VGX-3100 is the first DNA medicine to achieve efficacy endpoints [...]

Published
2021

161. Antiretroviral therapy: the 'when to start' debates

Author

Cohen, Calvin J. and Boyle, Brian A.

Subjects
Communicable diseases -- Drug therapy, HIV infection -- Drug therapy, Antiviral agents -- Dosage and administration, Health, Health care industry
Published
2004

164. Combating antibiotic resistance

Subjects
Communicable diseases -- Drug therapy, Drug resistance in microorganisms -- Research, Drug resistance in microorganisms -- Forecasts and trends, Antibacterial agents -- Dosage and administration, Market trend/market analysis, Health
Abstract

An alarming increase in drug-resistant bacterial infections due to the widespread use of antibiotics by health professions and the livestock industry is discussed. Dental practitioners as health care providers should use antibacterial drugs in an appropriate manner, which will extend the efficacy of the drug that, forms the treatment for many infectious diseases.

Published
2004

165. Fluoroquinolone resistance in Streptococcus pyogenes. (Brief Report)

Author

Richter, Sandra S., Diekema, Daniel J., Heilmann, Kris P., Almer, Laurel S., Shortridge, Virginia D., Zeitler, Rod, Flamm, Robert K., and Doern, Gary V.

Subjects
Streptococcus pyogenes -- Drug therapy, Streptococcus pyogenes -- Genetic aspects, Drug resistance in microorganisms -- Research, Quinolone antibacterial agents -- Physiological aspects, Quinolone antibacterial agents -- Usage, Communicable diseases -- Drug therapy, Communicable diseases -- Research, Quinolones, Health, Health care industry
Published
2003

166. On the implications of endogenous resistance to medications

Author

Laxminarayan, Ramanan and Weitzman, Martin L.

Subjects
Communicable diseases -- Drug therapy, Drug resistance -- Analysis, Drug therapy, Combination -- Planning, Health care industry -- Services, Business, Economics, Health care industry
Abstract

An analysis of the efficiency of using combined drug therapies in treating infectious diseases rather than a uniform drug treatment due to endogenous resistance to drugs is offered. Additional information on the model of endogenous resistance to drug therapies and optimal drug combination therapies is included.

Published
2002

167. Supply Of Medicines For The Treatment Of Patients With A New Coronavirus Infection (covid-19), An Infectious Diseases Hospital In Volgodonsk

Subjects
Communicable diseases -- Drug therapy, Drugs -- Health aspects, Infection -- Drug therapy, Coronaviruses -- Health aspects, Business, international
Abstract

Tenders are invited for supply of medicines for the treatment of patients with a new coronavirus infection (covid-19), an infectious diseases hospital in volgodonsk Supply of medicines for the treatment [...]

Published
2021

168. INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18

Subjects
Inovio Pharmaceuticals Inc., Communicable diseases -- Drug therapy, Dysplasia -- Drug therapy, Biotechnology industry, Immunotherapy, Papillomavirus infections -- Drug therapy, Business, News, opinion and commentary
Abstract

- DNA immunotherapy candidate VGX-3100 demonstrated clinically significant reduction of HPV-16/18-associated precancerous vulvar lesions in 63% of treated participants six months after treatment - Phase 2 results indicate that VGX-3100 [...]

Published
2021

169. INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Anal Dysplasia Caused by HPV-16/18

Subjects
Inovio Pharmaceuticals Inc., Communicable diseases -- Drug therapy, Dysplasia -- Drug therapy, Biotechnology industry, Immunotherapy, Papillomavirus infections -- Drug therapy, Lasers in surgery, Lasers in medicine, Business, News, opinion and commentary
Abstract

DNA immunotherapy candidate VGX-3100 demonstrated resolution of HPV-16/18-associated precancerous anal lesions in 50% of treated patients six months after treatment Current standard of care for anal dysplasia typically requires surgical [...]

Published
2020

170. New Autoimmunity Study Results from University of Birmingham Described (Manipulating Antigen Presentation for Antigen-specific Immunotherapy of Autoimmune Diseases)

Subjects
Communicable diseases -- Drug therapy, Autoimmunity, Immunotherapy, Antigens, Autoimmune diseases -- Drug therapy, Health, University of Birmingham
Abstract

2021 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on Immunology - Autoimmunity have been published. According to news originating from [...]

Published
2021

171. Nice shot: why vaccines are pharma' s next big thing

Author

Scudellart, Megan

Subjects
Pharmaceutical industry -- Industry forecasts, Pharmaceutical industry -- Product development, Communicable diseases -- Control, Communicable diseases -- Drug therapy, Bacterial vaccines -- Product development, Biological sciences
Published
2010

172. Molecular regulation of beta-lactam biosynthesis in filamentous fungi

Author

Brakhage, Axel A.

Subjects
Beta lactam antibiotics -- Research, Communicable diseases -- Drug therapy, Molds (Fungi) -- Research, Biological sciences
Abstract

Studies on the regulation of biosynthesis of beta-lactam antibiotics were conducted to help elucidate the physiological and ecological functions of beta-lactams for the producing fungi. Biosynthetic pathways leading to penicillin and cephalosporin, two most common beta-lactam antibiotics, begin from the same three amino acid precursors and possess the first two enzymatic reactions in common. Findings suggest that fungal beta-lactam biosynthesis is regulated by a complex regulatory network.

Published
1998

173. INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)

Subjects
Inovio Pharmaceuticals Inc. -- Product development, Communicable diseases -- Drug therapy, DNA, Biotechnology industry -- Product development, Papillomavirus infections -- Drug therapy, Drugs -- Product development, Business, News, opinion and commentary
Abstract

PLYMOUTH MEETING, Pa., Nov. 23, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious [...]

Published
2020

174. Sensei Biotherapeutics Presents Additional Data from Phase 1/2 Clinical Trial of SNS-301 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Subjects
Clinical trials, Communicable diseases -- Drug therapy, Medical research, Immunotherapy, Pembrolizumab, Squamous cell carcinoma -- Drug therapy, Business, Business, international
Abstract

- SNS-301 demonstrated prolonged partial response and improvement in immune markers in PD-L1 negative disease patient with 43% tumor reduction - 30+ week stable disease observed in 2 patients BOSTON, [...]

Published
2020

175. RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections

Subjects
United States. Food and Drug Administration -- Officials and employees, Rifabutin -- Health aspects, Communicable diseases -- Drug therapy, Orphan drugs -- Health aspects, Infection -- Drug therapy, Drug approval -- Health aspects, Biological products industry -- Officials and employees, Business, international, Law
Abstract

(GlobeNewswire) - RedHill Biopharma Ltd. (Nasdaq: RDHL) (RedHill or the Company), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation [...]

Published
2020

176. Shionogi Announces Publication of Two Studies in The Lancet Infectious Diseases Highlighting the Efficacy and Safety of FETROJA[R] for the Treatment of Infections Due to Aerobic Gram-negative Bacteria in Adults With Limited Treatment Options

Subjects
Shionogi & Company Ltd., Communicable diseases -- Drug therapy, Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Bacterial pneumonia -- Drug therapy, Bacteria -- Health aspects, Beta lactamases -- Health aspects, Drug resistance -- Drug therapy, Pneumonia -- Drug therapy, Adults -- Health aspects, Pharmaceutical industry -- Health aspects, Business, Business, international, Fetroja (Medication) -- Health aspects
Abstract

* Shionogi announces publication of data from two of its clinical trials; APEKS-NP and CREDIBLE-CR in the journal The Lancet Infectious Diseases * APEKS-NP demonstrated that FETROJA (cefiderocol) is an [...]

Published
2020

177. BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia

Subjects
United States. National Institute of Allergy and Infectious Diseases, Communicable diseases -- Drug therapy, Microbial drug resistance -- Drug therapy, Pneumonia -- Drug therapy, Medical research, COVID-19 -- Drug therapy, Meropenem, Business, international, Law
Abstract

(GlobeNewswire) - BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announces publication of Recombinant Human [...]

Published
2020

178. C-Path launches Cure Drug Repurposing Collaboratory to treat infectious diseases, COVID-19

Subjects
United States. Food and Drug Administration, United States. National Center for Advancing Translational Sciences, Drugs, Communicable diseases -- Drug therapy, Drug approval, Health care reform, COVID-19 -- Drug therapy, Business, international, Law
Abstract

As millions of patients struggle with diseases that lack adequate treatments, there is a critical need to understand how existing drugs can be used in new ways to improve clinical [...]

Published
2020

179. C-Path Launches CURE Drug Repurposing Collaboratory to Accelerate Identification of New Uses of Existing Drugs to Treat Infectious Diseases, Including COVID-19

Subjects
Health care reform, Communicable diseases -- Drug therapy, Drugs, Drug approval, Business, News, opinion and commentary
Abstract

Clinicians to report novel uses of existing drugs through FDA-NCATS CURE ID Mobile App TUCSON, Ariz., June 23, 2020 /PRNewswire/ -- As millions of patients struggle with diseases that lack [...]

Published
2020

180. Shionogi & Co.,Ltd.: CAPSTONE-2 study of Xofluza(R) (Baloxavir Marboxil) for the Treatment of Influenza Published in The Lancet Infectious Diseases

Subjects
Shionogi & Company Ltd. -- Reports, Communicable diseases -- Drug therapy, Medical research -- Reports, Influenza -- Drug therapy, Pharmaceutical industry -- Reports, Baloxavir marboxil, Diseases, General interest, News, opinion and commentary, Xofluza (Medication) -- Reports
Abstract

Tokyo: Shionogi & Co.,Ltd. has issued the following news release: Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter 'Shionogi') announced today that the [...]

Published
2020

181. Tiziana Life Sciences announces that its Scientific Advisory Board Chairman Dr. Howard Weiner received NIH grant to investigate Nasal Anti-CD3 for the treatment of Alzheimers disease

Subjects
United States. National Institutes of Health -- Investigations -- Government finance, Anti-Alzheimer's disease agents -- Investigations -- Government finance, Chairpersons -- Investigations -- Government finance, Monoclonal antibodies -- Investigations -- Government finance, Communicable diseases -- Drug therapy, Biotechnology industries -- Government finance -- Investigations, Alzheimer's disease -- Drug therapy, Grants-in-aid -- Government finance -- Investigations, Antibodies, Inflammation, Research funding, Diseases, Company legal issue, Business, international, Law, Brigham and Women's Hospital -- Investigations
Abstract

(GlobeNewswire) - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the Chairman of the [...]

Published
2020

182. Tiziana Life Sciences announces that its Scientific Advisory Board Chairman Dr. Howard Weiner received NIH grant to investigate Nasal Anti-CD3 for the treatment of Alzheimer's disease

Subjects
United States. National Institutes of Health -- Investigations -- Government finance, Anti-Alzheimer's disease agents -- Investigations -- Government finance, Chairpersons -- Investigations -- Government finance, Communicable diseases -- Drug therapy, Biotechnology industries -- Government finance -- Investigations, Alzheimer's disease -- Drug therapy, Grants-in-aid -- Government finance -- Investigations, Inflammation, Research funding, Diseases, Company legal issue, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, June 04, 2020 (GLOBE NEWSWIRE) -- [...]

Published
2020

183. Tiziana Life Sciences announces that its Scientific Advisory Board Chairman Dr. Howard Weiner received NIH grant to investigate Nasal Anti-CD3 for the treatment of Alzheimer's disease

Subjects
United States. National Institutes of Health -- Investigations -- Government finance, Anti-Alzheimer's disease agents -- Investigations -- Government finance, Chairpersons -- Investigations -- Government finance, Communicable diseases -- Drug therapy, Biotechnology industries -- Government finance -- Investigations, Alzheimer's disease -- Drug therapy, Grants-in-aid -- Government finance -- Investigations, Inflammation, Research funding, Diseases, Company legal issue, Banking, finance and accounting industries, Business
Abstract

NEW YORK and LONDON, June 04, Jun 04, 2020 (GLOBE NEWSWIRE via COMTEX) -- This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Tiziana [...]

Published
2020

184. Infectious Disease Connect and ILUM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship

Subjects
Merck & Company Inc., Communicable diseases -- Drug therapy, Pharmaceutical industry, Antibiotics, Physicians, Technology, Decision making, Hospitals, Health, Telemedicine, Diseases, General interest, News, opinion and commentary
Abstract

PITTSBURGH: Merck & Co., Inc. has issued the following news release: Merck (NYSE: MRK), known as MSD outside the United States and Canada, and UPMC today announced that Infectious Disease [...]

Published
2020

185. Infectious Disease Connect and ILM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship

Subjects
Merck & Company Inc., Hospitals -- United States, Communicable diseases -- Drug therapy, Pharmaceutical industry, World health, Antibiotics, Technology, Telemedicine, Diseases, Investments, Business, Business, international
Abstract

Agreement Includes Strategic Investments from UPMC Enterprises and Merck Global Health Innovation Fund KENILWORTH, N.J. & PITTSBURGH -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, [...]

Published
2020

186. SCHOOL OF AEROSPACE MEDICINE TRAINS TEAMS TO TREAT, TRANSPORT COVID-19 PATIENTS

Subjects
United States. Air Force. Research Laboratory -- Training, Military training, Communicable diseases -- Drug therapy, Medical personnel -- Training, Air forces, Infection control, COVID-19 -- Drug therapy, News, opinion and commentary
Abstract

JOINT BASE CHARLESTON, S.C. (AFNS) -- The following information was released by the Air Reserve Personnel Center: By Gina Marie Giardina, Air Force Research Laboratory Medical professionals from the U.S. [...]

Published
2020

187. Arrevus Receives FDA Qualified Infectious Disease Product (QIDP) Designation for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

Subjects
United States. Food and Drug Administration, Cystic fibrosis -- Drug therapy, Communicable diseases -- Drug therapy, Antibiotics, Fibrosis, Lung diseases, Diseases, General interest, News, opinion and commentary
Abstract

RALEIGH: Arrevus has issued the following press release: Arrevus today announced the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation for ARV-1801 (sodium fusidate [...]

Published
2020

188. Researchers from Research Center Report Details of New Studies and Findings in the Area of Tuberculosis (Personalized Medicine for Chronic Respiratory Infectious Diseases: Tuberculosis, Nontuberculous Mycobacterial Pulmonary Diseases, and ...)

Subjects
Precision medicine, Physical fitness, Communicable diseases -- Drug therapy, Medical research, Lung diseases -- Drug therapy, Tuberculosis -- Drug therapy, Health
Abstract

2017 OCT 7 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Mycobacterium Infections - Tuberculosis. According to news [...]

Published
2017

189. Studies from Pacific Northwest National Laboratory Reveal New Findings on Pulmonary Tuberculosis (Nutritional Markers and Proteome In Patients Undergoing Treatment for Pulmonary Tuberculosis Differ By Geographic Region)

Subjects
United States. Pacific Northwest National Laboratory, Pulmonary tuberculosis -- Drug therapy, Communicable diseases -- Drug therapy, Respiratory agents, Health, Public Library of Science
Abstract

2021 AUG 17 (NewsRx) -- By a News Reporter-Staff News Editor at TB & Outbreaks Week -- Investigators publish new report on Lung Diseases and Conditions - Pulmonary Tuberculosis. According [...]

Published
2021

190. Findings on Legionnaires' Disease Detailed by Investigators at William S. Middleton Memorial Veterans Hospital (Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? a Systematic Review and Meta-analysis)

Subjects
Communicable diseases -- Drug therapy, Medical research, Medicine, Experimental, Bacterial pneumonia -- Drug therapy, Quinolone antibacterial agents, Hospitals, Veterans', Quinolones, Pneumonia -- Drug therapy, Health
Abstract

2021 AUG 17 (NewsRx) -- By a News Reporter-Staff News Editor at TB & Outbreaks Week -- Current study results on Lung Diseases and Conditions - Legionnaires' Disease have been [...]

Published
2021

191. Studies from National Institute of Infectious Diseases and Vaccinology Describe New Findings in Cancer (A Novel Recombinant Fcg Receptor-Targeted Survivin Combines with Chemotherapy for Efficient Cancer Treatment)

Subjects
Oncology, Experimental -- Reports, Communicable diseases -- Drug therapy, Chemotherapy -- Reports, Vaccines -- Reports, Cancer -- Chemotherapy -- Research, Health
Abstract

2021 AUG 11 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Fresh data on cancer are presented in a new report. According to news reporting out [...]

Published
2021

192. Nigeria: Taking Diabetes Treatment to Rural Communities

Subjects
Health screening, Hypertension -- Drug therapy, Communicable diseases -- Drug therapy, Diabetes therapy, Teachers, Kidney failure, Public health, News, opinion and commentary
Abstract

Adibe Emenyonu writes on the free diabetes, hypertension screening and treatment conducted by the University of Benin Teaching Hospital in partnership with Sanofi Pharmaceuticals to mark the World Diabetes Day [...]

Published
2019

194. When Should I Take an Antibiotic?

Author

Klasco, Richard

Subjects
Antibiotics -- Health aspects -- Dosage and administration, Bacterial infections -- Drug therapy, Communicable diseases -- Drug therapy, Heart rate -- Health aspects, Virus diseases -- Drug therapy, Respiratory tract diseases, Cardiac patients, Bronchitis, Infection, General interest, News, opinion and commentary
Abstract

Q. I know that antibiotics don't treat viruses, but at some point, isn't it time to try one?A. With the caveat that medical expertise is required to differentiate bacterial illnesses [...]

Published
2019

196. Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge

Author

Edghill-Smith, Yvette, Bray, Mike, Whitehouse, Chris A., Miller, David, Mucker, Eric, Manischewitz, Jody, King, Lisa R., Robert-Guroff, Marjorie, Hryniewicz, Anna, Venzon, David, Meseda, Clement, Weir, Jerry, Nalca, Aysegul, Livingston, Virginia, Wells, Jay, Lewis, Mark G., Huggins, John, Zwiers, Susan H., Golding, Hana, and Franchini, Genoveffa

Subjects
Communicable diseases -- Drug therapy, HIV infection -- Drug therapy, Smallpox vaccine -- Dosage and administration, Medical research, Medicine, Experimental, Health
Published
2005

198. Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand

Author

Ashley, Elizabeth A., Krudsood, Srivicha, Phaiphun, Lucy, Srivilairit, Siripan, McGready, Rose, Leowattana, Wattana, Hutagalung, Robert, Wilairatana, Polrat, Brockman, Alan, Looareesuwan, Sornchai, Nosten, Francois, and White, Nicholas J.

Subjects
Communicable diseases -- Complications, Communicable diseases -- Drug therapy, Malaria -- Complications, Malaria -- Drug therapy, Health
Published
2004

199. Physicians slow to use new antibiotics against superbugs

Subjects
Physicians -- Beliefs, opinions and attitudes, Antibiotics -- Dosage and administration -- Product development, Communicable diseases -- Drug therapy, Business, Health care industry
Abstract

New, more effective antibiotics are being prescribed in only about a quarter of infections by carbapenem-resistant Enterobacteriaceae (CRE), a family of the world's most intractable drug-resistant bacteria, according to an [...]

Published
2020

200. Update in infectious diseases

Author

Sande, Merle A. and Ronald, Allan R.

Subjects
Severe acute respiratory syndrome -- Research, Vaccines -- Health aspects, Communicable diseases -- Drug therapy, Health
Abstract

Severe acute respiratory syndrome, hepatitis B, respiratory viruses, antibiotic resistance, and vaccination are the focus areas of 2004 update in infectious diseases. New vaccines and effective therapies for infectious diseases are discovered.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results